Skip to content

Price / book at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Opko Health logo
Opko HealthOPK
0.7×-0.1×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
2.8×+2.2×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
2.7×-7.2×
ALN
Alnylam PharmaceuticalsALNY
40.8×-41.2×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
2.4×+1.5×

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+110%
Enterprise value$1.07B+102%
P/S13.5×-1.4×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Calculated from MeiraGTx Holdings plc’s reported figures.

Based on the most recent quarter.

The official record: MeiraGTx Holdings plc’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's price / book?
MeiraGTx Holdings plc (MGTX) reported price / book of 174.8× in Q2 2025.
How has MeiraGTx Holdings plc's price / book changed year-over-year?
MeiraGTx Holdings plc's price / book increased by 5088.7% year-over-year, from 3.4× to 174.8×.
What is the long-term trend for MeiraGTx Holdings plc's price / book?
Over 4 years (2020 to 2024), MeiraGTx Holdings plc's price / book has grown at a 25.6% compound annual growth rate (CAGR), from 2.8× to 7×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.